Viramal — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Viramal is a private, clinical-stage biotech company pioneering women's health therapeutics through its proprietary Fem Med Tech™ platform. Founded in 2013 (incorporated 2017), the company is developing a pipeline of prescription and non-prescription products for conditions like endometriosis, menopause, and chronic pelvic pain, emphasizing targeted, non-invasive delivery to avoid systemic side effects. Led by a team with deep experience in women's health and biotech, Viramal operates from London and Sweden, targeting a large, underserved market with therapies designed to be more tolerable and effective than current standards. The company is currently pre-revenue, advancing its portfolio through clinical development.

Women's HealthReproductive HealthEndocrinologyPain Management

Technology Platform

Proprietary Fem Med Tech™ platform focusing on targeted, non-invasive drug delivery via transdermal, buccal, and vaginal routes to maximize efficacy and minimize systemic side effects.

Opportunities

The significant and growing unmet need in women's health represents a large, underserved market.

Increasing societal focus and destigmatization of women's health issues create a favorable environment for innovative solutions.

The company's targeted delivery approach could establish a new standard of care for safer, more effective treatments.

Risk Factors

High risk of clinical trial failure inherent to drug development.

Dependence on securing ongoing financing as a pre-revenue company.

Potential challenges in convincing physicians and patients to adopt novel delivery methods over established, albeit suboptimal, treatments.

Competitive Landscape

Competition includes large pharmaceutical companies with hormone therapies and pain medications, as well as a growing number of biotech startups focused on women's health. Viramal's differentiation lies in its specific Fem Med Tech™ platform for localized delivery, aiming for superior safety and tolerability versus systemic drugs.

More companies in Small Molecule Drugs →More companies in United Kingdom →